Alto Neuroscience (NYSE:ANRO) Stock Price Up 6.5% – What’s Next?

Alto Neuroscience, Inc. (NYSE:ANRO) rose 6.5% during trading on Tuesday . The stock traded as high as $24.18 and last traded at $24.4190. Approximately 31,965 shares changed hands during mid-day trading, a decline of 89% from the average daily volume of 288,659 shares. The stock had previously closed at $22.93.

Analyst Ratings Changes

ANRO has been the subject of several research reports. HC Wainwright reiterated a “buy” rating on shares of Alto Neuroscience in a research note on Wednesday, June 17th. Jefferies Financial Group reiterated a “buy” rating and issued a $35.00 price target on shares of Alto Neuroscience in a report on Monday, March 16th. Wolfe Research started coverage on Alto Neuroscience in a research note on Friday, May 22nd. They set an “outperform” rating on the stock. Wedbush upped their target price on Alto Neuroscience from $21.00 to $24.00 and gave the stock a “neutral” rating in a research report on Thursday, May 14th. Finally, Weiss Ratings upgraded Alto Neuroscience from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, May 1st. Eight research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $35.25.

Alto Neuroscience Price Performance

The company has a current ratio of 20.52, a quick ratio of 20.52 and a debt-to-equity ratio of 0.07. The stock has a market cap of $889.77 million, a PE ratio of -10.47 and a beta of 1.24. The company’s 50 day moving average is $22.74 and its 200-day moving average is $19.92.

Alto Neuroscience (NYSE:ANRO) last announced its earnings results on Wednesday, May 13th. The company reported ($0.80) earnings per share for the quarter, missing the consensus estimate of ($0.56) by ($0.24). As a group, sell-side analysts predict that Alto Neuroscience, Inc. will post -3.01 earnings per share for the current year.

Institutional Investors Weigh In On Alto Neuroscience

Several hedge funds and other institutional investors have recently bought and sold shares of ANRO. Quantinno Capital Management LP raised its position in shares of Alto Neuroscience by 1.4% in the 1st quarter. Quantinno Capital Management LP now owns 36,069 shares of the company’s stock valued at $811,000 after purchasing an additional 490 shares in the last quarter. Peapod Lane Capital LLC grew its position in shares of Alto Neuroscience by 1.1% during the third quarter. Peapod Lane Capital LLC now owns 281,963 shares of the company’s stock worth $1,136,000 after buying an additional 3,106 shares in the last quarter. Torren Management LLC acquired a new stake in shares of Alto Neuroscience during the fourth quarter worth approximately $62,000. XTX Topco Ltd increased its stake in shares of Alto Neuroscience by 32.2% in the fourth quarter. XTX Topco Ltd now owns 20,824 shares of the company’s stock worth $371,000 after buying an additional 5,078 shares during the last quarter. Finally, Renaissance Technologies LLC increased its stake in shares of Alto Neuroscience by 6.3% in the first quarter. Renaissance Technologies LLC now owns 103,499 shares of the company’s stock worth $2,327,000 after buying an additional 6,100 shares during the last quarter.

Alto Neuroscience Company Profile

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.